Omega-3 phospholipid - Acasti Pharma

Drug Profile

Omega-3 phospholipid - Acasti Pharma

Alternative Names: CaPre; NKPL-66

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acasti Pharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids; Phospholipids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 14 Aug 2017 Acasti Pharma plans to initiate phase III programme in Hypertriglyceridaemia in December 2017
  • 24 Apr 2017 Acasti Pharma is granted additional patents for NKPL 66 in Australia and Taiwan
  • 30 Mar 2017 Acasti plans two phase III clinical trials for Hypertriglyceridaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top